Study design and patients
cancer, bone marrow hematopoietic function, high‐intensity, myelosuppression, Cancer
ONCOLOGY, CANCER, PEDIATRIC CANCER, CANCER
This prospective study enrolled pediatric cancer patients receiving high‐intensity chemotherapy resulting in grade ≥3 myelosuppression (determined by the investigators) in five clinical centers between October 2020 and March 2022.The inclusion criteria were (1) ≤18 years of age, (2) confirmed cancer by histopathology or bone marrow cytology, (3) Eastern Cooperative Oncology Group (ECOG) score ≤2, (4) expected survival >8 months, (5) normal bone marrow hematopoietic function [absolute neutrophil count (ANC) ≥1.5 × 10This study was approved by the Ethics Committee of the Cancer Center of Sun Yat‐sen University (approval number: B2020‐202‐01). Informed consent was provided by each participant or their legal guardian. This trial was registered (